MRI-Guided Drug Delivery

Strategic Alliance with Brainlab in MRI-Guided Drug Delivery

In April 2011, Brainlab and MRI Interventions announced a collaboration aimed at integrating our ClearPoint® product line with Brainlab’s iMRI product line, with particular focus on local delivery of drugs and other therapeutic agents to precision targets in the brain under MRI guidance. We and Brainlab both believe the integration of these technologies could, subject to appropriate regulatory clearance or approval, enable patient-specific treatment planning, simplified clinical workflows and optimal delivery of drugs to the brain.  

In connection with the announcement, Dr. Krystof Bankiewicz, Vice Chair and Professor, Department of Neurosurgery and Director of the NeuroTherapeutics Delivery Center at the University of California San Francisco made the following comment: “Direct, image-guided delivery of therapeutic agents into the brain provides the next generation platform for delivering a wide range of promising therapies for patients suffering from CNS disorders such as Parkinson’s disease and malignant brain tumors.  This collaboration between two important players in the field is welcome news to pharmaceutical companies, biotech companies and researchers with therapeutic agents that need to be delivered in a targeted, patient-specific, image-guided fashion.”

SmartFlow® Neuro Ventricular Cannula

In January 2011, we received 510(k) clearance from the FDA for our SmartFlow neuro ventricular cannula. Our SmartFlow cannula, which is compatible with our ClearPoint system, is an MRI-compatible injection and aspiration cannula. It is indicated for use in the injection of Cytarabine, which is a chemotherapy drug, or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure. The SmartFlow cannula is a disposable device intended for single patient use only and is not intended for implant.